Medication info

Regent Duo Tablet 2.5/500 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin Micronized›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Bright yellow, oval-shaped, film-coated tablets with a biconvex surface
Packaging
60 tablets (10 T/PTP * 6)
Approval status
Expired

MFDS item code 201905462 · Approved 2019.07.31

This product's status changed to Expired on 2024.07.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). No studies have been conducted to investigate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients Who Must Not Take This Medicine).

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in Blood Sugar Control
View approved original text

This medication is used as an adjunct to dietary and exercise therapy to help control blood sugar in adult patients with type 2 diabetes. It may be administered when blood sugar control is difficult with monotherapy for those who have not previously used diabetes medications. It is also used when substituting for the combined therapy of linagliptin and metformin. If blood sugar control is insufficient with the combined therapy of insulin and metformin, this medication can be used in conjunction with insulin. Finally, if control remains difficult with the maximum dose of metformin combined with empagliflozin, this medication may be administered together with empagliflozin. This helps improve blood sugar control in various scenarios.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). No studies have been conducted to investigate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients Who Must Not Take This Medicine).

Precautions

This medication contains metformin hydrochloride and linagliptin and is used for blood sugar control. Care should be taken when consuming this medication because lactic acidosis, a serious metabolic complication, may occur. While rare, it has a higher risk of occurrence in severe conditions such as acute renal function deterioration, cardiopulmonary disease, or sepsis. Especially, patients with allergies to this medication's components, type 1 diabetes, lactic acidosis, diabetic ketoacidosis, or severe renal impairment should not take this medication. It should also be avoided in the presence of acute conditions that may affect renal function, such as dehydration, severe infections, major trauma, acute myocardial infarction, or shock. It is safest not to use this medication in patients with liver dysfunction or severe gastrointestinal disorders, or in cases of acute alcohol intoxication or alcohol dependence. Women who are pregnant or breastfeeding should also avoid this medication and consult a doctor for alternative treatment methods if they plan to become pregnant. When taking this medication in conjunction with sulfonylureas or insulin, the risk of hypoglycemia may increase; therefore, blood sugar levels should be checked regularly, and dosage adjustments may be necessary. Kidney function is closely related to the excretion of this medication, so regular kidney function tests should be conducted before and during treatment, and extra caution is needed for elderly patients with diminished kidney function. During treatment with this medication, rare skin conditions such as acute pancreatitis or necrotizing fasciitis may occur, so if there are persistent and severe abdominal pains or skin blisters, immediate medical attention should be sought. Long-term use may decrease vitamin B12 levels, so if symptoms of anemia or neurological issues appear, a blood test to check vitamin B12 levels should be performed, and supplementation may be needed. This medication may interact with other drugs; therefore, especially in cases of concurrent use with drugs that affect renal function or either potentiate or diminish blood sugar-lowering effects, consultation with a doctor or pharmacist is advised. When using iodine-based contrast agents during radiological exams, there is a risk of kidney function deterioration and lactic acidosis; therefore, this medication should be discontinued for a certain period before and after the exam and should be resumed only after kidney function stabilizes. This medication should also be paused for a period before and after any surgical procedures, and reinstitution should only occur after confirming recovery of kidney function. Elderly patients are often at risk for diminished kidney function, so it is essential to adjust dosages and conduct regular kidney function tests. In the event of an overdose, the risk of lactic acidosis increases, so immediate hospital treatment is required, and as necessary, dialysis may be performed to remove the medication from the system. This medication should be stored out of the reach of children, protected from moisture, and it is advisable not to transfer it to other containers.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorders
  • cough
  • decreased appetite
Show 169 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • dermatitis herpetiformis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • itching
  • hypertension
  • benign prostatic hyperplasia
  • vitreous hemorrhage
  • confusion state
  • nocturia
  • dermatitis
  • myelodysplastic syndrome
  • angina
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • dysphagia
  • gastric ulcer
  • gum bleeding
  • tooth loss
  • hemorrhoids
  • lower abdominal pain
  • viral upper respiratory infection
  • periodontitis
  • influenza
  • folliculitis
  • gingivitis
  • hypercholesterolemia
  • malnutrition
  • hyponatremia
  • dizziness
  • sensory loss
  • chest discomfort
  • asthenia
  • pain
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • epistaxis
  • exercise-induced dyspnea
  • wet cough
  • rhinorrhea
  • lung mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • increased serum triglycerides
  • increased urine albumin/creatinine ratio
  • positive urine leukocytes
  • decreased hemoglobin
  • increased serum potassium
  • increased serum creatinine
  • increased serum creatine phosphokinase
  • increased ALT
  • increased AST
  • male pattern baldness
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • depression
  • hypertension
  • benign prostatic hyperplasia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and humidity, so it should be stored in a sealed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius. This helps to maintain the medication’s effectiveness for a longer period.

Appearance and packaging

Appearance

Bright yellow, oval-shaped, film-coated tablets with a biconvex surface

Package unit

60 tablets (10 T/PTP * 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.